Volume 8 Issue 2-3
Oct.  2020
Turn off MathJax
Article Contents
Xin-yu REN, Li YUAN, Song-jie SHEN, Huan-wen WU, Jun-liang LU, Zhi-yong LIANG. Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 154-160. doi: 10.3969/j.issn.1674-9081.2017.03.013
Citation: Xin-yu REN, Li YUAN, Song-jie SHEN, Huan-wen WU, Jun-liang LU, Zhi-yong LIANG. Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 154-160. doi: 10.3969/j.issn.1674-9081.2017.03.013

Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer

doi: 10.3969/j.issn.1674-9081.2017.03.013
More Information
  • Corresponding author: MA Dong-jie   Tel: 010-69155969, Email:liangzhiyong1220@yahoo.com
  • Received Date: 2016-07-04
  • Publish Date: 2020-10-30
  •     Objective       To investigate the value of combined detection of CK5/6, CK14 and epidermal growth factor receptor (EGFR) in diagnosing basal-like subtype triple negative breast cancer (TNBC).    Methods       The clinical and pathological data of 115 patients diagnosed with TNBC were recorded from January 2000 to December 2011. The expression of CK5/6, CK14 and EGFR were detected with immunohistochemical methods using paraffin specimens. Combined detection result of the three markers was used as gold standard, then the sensitivity and specificity of CK5/6, CK14 and EGFR were detected by single marker and two combined assays.The differences between basal-like and non basal-like subtype TNBC in age, tumor size, tumor histological type and other clinicopathological issues were compared.    Results       The mean age of 115 patients with TNBC was (50.7±13.6) years. Immunhistochemical result showed that single marker positivity was 29.6% (34/115), 21.7% (18/83), and 60.9% (70/115) for CK5/6, CK14, and EGFR, respectively. Combined detection of the three markers, the positive rate was 67.8% (78/115). Taking three markers combination as a golden standard, the sensitivity and specificity of EGFR and CK5/6 combination were 98.7% and 100%. There were significant differences between basal-like and non basal-like subtype TNBC in histological type, tumor grade, lymph node metastasis and mortality(all P < 0.05). Survival analysis showed that the overall survival period of basal-like subtype TNBC was significant shortened(HR=0.363, 95% CI:0.139~0.947).    Conclusions       Combined detection of CK5/6, CK14 and EGFR could identifiy the largest number of basal-like subtype TNBC. The prognosis of basal-like subtype TNBC is worse than that of non basal-like subtype TNBC, and it is important to identify the subtype.
  • loading
  • [1] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406:747-752. doi:  10.1038/35021093
    [2] Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci USA, 2001, 98:10869-10874. doi:  10.1073/pnas.191367098
    [3] Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer:understanding the molecular basis of histologic grade to improve prognosis[J]. J Natl Cancer Inst, 2006, 98:262-272. doi:  10.1093/jnci/djj052
    [4] Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci USA, 2003, 100:8418-8423. doi:  10.1073/pnas.0932692100
    [5] Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population based study[J]. Proc Natl Acad Sci USA, 2003, 100:10393-10398. doi:  10.1073/pnas.1732912100
    [6] Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer:review[J]. Pathology, 2009, 41:40-47. http://www.sciencedirect.com/science/article/pii/S003130251632061X
    [7] Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10:5367-5374. doi:  10.1158/1078-0432.CCR-04-0220
    [8] Leidy J, Khan A, Kandil D.Basal-like breast cancer:update on clinicopathologic, immunohistochemical and moleculr features[J]. Arch Pathol Lab Med, 2014, 138:37-43. doi:  10.5858/arpa.2012-0439-RA
    [9] National Health Service Breast Screening Programme (NHSBSP) and The Royal College of Pathologists. Pathology Reporting of Breast Disease[M]. Sheffield:NHSBSP and The Royal College of Pathologists, 2005:58.
    [10] Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profilingto breast cancer classification, prognostication and prediction:a retrospective of the last decade[J]. J Pathol, 2010, 220:263-280. doi:  10.1002/path.2648
    [11] Nielsen TO, Hsu FD, Jensen K, et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004, 10:5367-5374. doi:  10.1158/1078-0432.CCR-04-0220
    [12] Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008, 14:1368-1376. doi:  10.1158/1078-0432.CCR-07-1658
    [13] Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers:a critical review with an emphasis on the implications for pathologists and oncologists[J]. Mod Pathol, 2011, 24:157-167. doi:  10.1038/modpathol.2010.200
    [14] Perou CM. Molecular Stratification of Triple-Negative Breast Cancers[J]. Oncologist, 2011, 16:61-70. doi:  10.1634/theoncologist.2010-S5-39
    [15] Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer:a comparison with hormone receptor and Her2/neu-overexpressing phenotypes[J]. Hum Pathol, 2006, 37:1217-1226. doi:  10.1016/j.humpath.2006.04.015
    [16] Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basallike subtype of invasive breast carcinoma[J]. Mod Pathol, 2006, 19:264-271. doi:  10.1038/modpathol.3800528
    [17] Rakha EA, Elsheikh SE, Aleskandarany MA, et al. Triple-negative breast cancer:distinguishing between basal and nonbasal subtypes[J]. Clin Cancer Res, 2009, 15:2302-2310. doi:  10.1158/1078-0432.CCR-08-2132
    [18] Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al.Basal-like phenotype is not associated with patient survival in estrogen-receptornegative breast cancers[J]. Breast Cancer Res, 2007, 9:R16. doi:  10.1186/bcr1649
    [19] Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers?[J].Int J Cancer, 2008, 123:236-240. doi:  10.1002/ijc.23518
    [20] Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J]. BMC Cancer, 2007, 7:134. doi:  10.1186/1471-2407-7-134
    [21] Bidard FC, Conforti R, Boulet T, et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers[J]. Ann Oncol, 2007, 18:1285-1286. doi:  10.1093/annonc/mdm360
    [22] Tan DS, Marchio C, Jones RL, et al. Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant anthracyclinetreated patients[J]. Breast Cancer Res Treat, 2008, 111:27-44. doi:  10.1007/s10549-007-9756-8
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(3)

    Article Metrics

    Article views (413) PDF downloads(6) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return